StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

Arrowhead Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Arrowhead Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$59.06M, down 370.3% year over year. For fiscal 2025 it was $179.55M. The highest annual figure on record is $179.55M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Sep 30, 2025$179.55M–
FY2024Sep 30, 2024-$462.85M–
FY2023Sep 30, 2023-$153.89M–
FY2022Sep 30, 2022-$136.13M-179.5%
FY2021Sep 30, 2021$171.31M–
FY2020Sep 30, 2020-$95.80M-155.4%
FY2019Sep 30, 2019$173.04M–
FY2018Sep 30, 2018-$47.22M–
FY2017Sep 30, 2017-$23.94M–
FY2016Sep 30, 2016-$64.43M–
FY2015Sep 30, 2015-$65.71M–
FY2014Sep 30, 2014-$35.42M–
FY2013Sep 30, 2013-$19.03M–
FY2012Sep 30, 2012-$15.34M–
FY2011Sep 30, 2011-$7.66M–
FY2010Sep 30, 2010-$5.05M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026-$177.47M–
Q2 FY2026CQ1 2026Mar 31, 2026$84.44M-81.6%
Q1 FY2026CQ4 2025Dec 31, 2025$13.48M–
Q4 FY2025CQ3 2025Sep 30, 2025$20.49M–
Q3 FY2025CQ2 2025Jun 30, 2025-$154.72M–
Q2 FY2025CQ1 2025Mar 31, 2025$460.05M–
Q1 FY2025CQ4 2024Dec 31, 2024-$146.27M–
Q4 FY2024CQ3 2024Sep 30, 2024-$137.22M–
Q3 FY2024CQ2 2024Jun 30, 2024-$115.42M–
Q2 FY2024CQ1 2024Mar 31, 2024-$92.38M–
Q1 FY2024CQ4 2023Dec 31, 2023-$117.84M–
Q4 FY2023CQ3 2023Sep 30, 2023-$25.93M–
Q3 FY2023CQ2 2023Jun 30, 2023-$20.78M–
Q2 FY2023CQ1 2023Mar 31, 2023-$31.67M-150.5%
Q1 FY2023CQ4 2022Dec 31, 2022-$75.52M–
Q4 FY2022CQ3 2022Sep 30, 2022-$68.74M–
Q3 FY2022CQ2 2022Jun 30, 2022-$68.82M–
Q2 FY2022CQ1 2022Mar 31, 2022$62.73M-76.2%
Q1 FY2022CQ4 2021Dec 31, 2021-$61.31M–
Q4 FY2021CQ3 2021Sep 30, 2021-$24.03M–
Q3 FY2021CQ2 2021Jun 30, 2021-$29.61M–
Q2 FY2021CQ1 2021Mar 31, 2021$263.87M–
Q1 FY2021CQ4 2020Dec 31, 2020-$38.92M–
Q4 FY2020CQ3 2020Sep 30, 2020-$11.26M-181.5%
Q3 FY2020CQ2 2020Jun 30, 2020-$33.43M-417.5%
Q2 FY2020CQ1 2020Mar 31, 2020-$27.59M–
Q1 FY2020CQ4 2019Dec 31, 2019-$23.53M-114.0%
Q4 FY2019CQ3 2019Sep 30, 2019$13.81M–
Q3 FY2019CQ2 2019Jun 30, 2019$10.53M–
Q2 FY2019CQ1 2019Mar 31, 2019-$19.59M–
Q1 FY2019CQ4 2018Dec 31, 2018$168.28M–
Q4 FY2018CQ3 2018Sep 30, 2018-$2.68M–
Q3 FY2018CQ2 2018Jun 30, 2018-$14.41M–
Q2 FY2018CQ1 2018Mar 31, 2018-$15.44M–
Q1 FY2018CQ4 2017Dec 31, 2017-$14.69M-246.9%
Q4 FY2017CQ3 2017Sep 30, 2017-$9.20M–
Q3 FY2017CQ2 2017Jun 30, 2017-$10.41M–
Q2 FY2017CQ1 2017Mar 31, 2017-$14.33M–
Q1 FY2017CQ4 2016Dec 31, 2016$10.00M–
Q4 FY2016CQ3 2016Sep 30, 2016-$10.18M–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?